- Home
- CDTX vs PZZA Comparison
CDTX vs PZZA Comparison
Compare CDTX & PZZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- PZZA
- Stock Information
- Founded
- CDTX 2012
- PZZA 1984
- Country
- CDTX United States
- PZZA United States
- Employees
- CDTX N/A
- PZZA N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- PZZA Restaurants
- Sector
- CDTX Health Care
- PZZA Consumer Discretionary
- Exchange
- CDTX Nasdaq
- PZZA Nasdaq
- Market Cap
- CDTX 1.4B
- PZZA 1.4B
- IPO Year
- CDTX 2015
- PZZA 1993
- Fundamental
- Price
- CDTX $66.37
- PZZA $46.29
- Analyst Decision
- CDTX Strong Buy
- PZZA Buy
- Analyst Count
- CDTX 11
- PZZA 10
- Target Price
- CDTX $57.00
- PZZA $52.33
- AVG Volume (30 Days)
- CDTX 427.5K
- PZZA 973.8K
- Earning Date
- CDTX 08-07-2025
- PZZA 08-07-2025
- Dividend Yield
- CDTX N/A
- PZZA 4.15%
- EPS Growth
- CDTX N/A
- PZZA 8.47
- EPS
- CDTX N/A
- PZZA 2.28
- Revenue
- CDTX N/A
- PZZA $2,085,052,000.00
- Revenue This Year
- CDTX N/A
- PZZA $4.40
- Revenue Next Year
- CDTX N/A
- PZZA $0.98
- P/E Ratio
- CDTX N/A
- PZZA $19.45
- Revenue Growth
- CDTX N/A
- PZZA N/A
- 52 Week Low
- CDTX $10.14
- PZZA $30.16
- 52 Week High
- CDTX $69.36
- PZZA $60.75
- Technical
- Relative Strength Index (RSI)
- CDTX 65.51
- PZZA 55.05
- Support Level
- CDTX $59.80
- PZZA $43.94
- Resistance Level
- CDTX $69.36
- PZZA $47.32
- Average True Range (ATR)
- CDTX 3.83
- PZZA 1.76
- MACD
- CDTX -0.38
- PZZA 0.27
- Stochastic Oscillator
- CDTX 76.70
- PZZA 75.43
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.